AVTE
Price:
$1.9
Market Cap:
$54.85M
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.[Read more]
Industry
Biotechnology
IPO Date
2021-06-30
Stock Exchange
NASDAQ
Ticker
AVTE
According to Aerovate Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.61. This represents a change of -89.00% compared to the average of -5.54 of the last 4 quarters.
The mean historical PE Ratio of Aerovate Therapeutics, Inc. over the last ten years is -52.67. The current -0.61 PE Ratio has changed 15.81% with respect to the historical average. Over the past ten years (40 quarters), AVTE's PE Ratio was at its highest in in the June 2021 quarter at -0.24. The PE Ratio was at its lowest in in the March 2021 quarter at -44.28.
Average
-52.67
Median
-13.92
Minimum
-167.35
Maximum
-7.89
Discovering the peaks and valleys of Aerovate Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 11.07%
Maximum Annual PE Ratio = -7.89
Minimum Annual Increase = -79.67%
Minimum Annual PE Ratio = -167.35
Year | PE Ratio | Change |
---|---|---|
2023 | -7.89 | -43.32% |
2022 | -13.92 | 11.07% |
2021 | -12.53 | -79.67% |
2020 | -61.65 | -63.16% |
The current PE Ratio of Aerovate Therapeutics, Inc. (AVTE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-11.45
5-year avg
-52.67
10-year avg
-52.67
Aerovate Therapeutics, Inc.’s PE Ratio is greater than Adagene Inc. (-2.86), greater than Acrivon Therapeutics, Inc. Common Stock (-4.23), greater than Rezolute, Inc. (-3.80), less than AN2 Therapeutics, Inc. (-0.47), greater than Anebulo Pharmaceuticals, Inc. (-4.99), greater than Opthea Limited (-1.11), greater than Mineralys Therapeutics, Inc. (-4.63),
Company | PE Ratio | Market cap |
---|---|---|
-2.86 | $115.55M | |
-4.23 | $250.26M | |
-3.80 | $240.80M | |
-0.47 | $30.44M | |
-4.99 | $46.68M | |
-1.11 | $444.73M | |
-4.63 | $558.43M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aerovate Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Aerovate Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Aerovate Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Aerovate Therapeutics, Inc. (AVTE)?
What is the highest PE Ratio for Aerovate Therapeutics, Inc. (AVTE)?
What is the 3-year average PE Ratio for Aerovate Therapeutics, Inc. (AVTE)?
What is the 5-year average PE Ratio for Aerovate Therapeutics, Inc. (AVTE)?
How does the current PE Ratio for Aerovate Therapeutics, Inc. (AVTE) compare to its historical average?